Fig. 4
From: The therapeutic potential of pegylated arginase I treatment in glioblastoma
BCT-100 combined with CQ but not TMZ or DFMO to enhance cytotoxicity. (a) (i-iv) The cytotoxicity responses of U87, U373, U138, and D54, respectively, treated with or without 1 U/ml BCT-100 and/or 100 µM TMZ according to annexin V/propidium iodide assay. **p < 0.01 compared between 0.2% DMSO and 100 µM TMZ. *p < 0.05 compared between 0.2% DMSO and 100 µM TMZ. (b) (i-iv) Cytotoxicity responses of U87, U373, U138, and D54, respectively, treated with or without 1 U/ml BCT-100 and/or 5 mM DFMO, according to annexin V/propidium iodide assay. (c) (i-iv) Cytotoxicity responses of U87, U373, U138, and D54, respectively, treated with or without 1 U/ml BCT-100 and/or 5 µM CQ according to annexin V/propidium iodide assay. **p < 0.01 compared between BCT-100 alone and CQ + BCT-100. *p < 0.05 compared between BCT-100 alone and CQ + BCT-100.
